Immutep (ASX:IMM) EV-to-EBIT: (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Immutep EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Immutep's Enterprise Value is A$-24.23 Mil. Immutep's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil. Therefore, Immutep's EV-to-EBIT for today is .

The historical rank and industry rank for Immutep's EV-to-EBIT or its related term are showing as below:

ASX:IMM' s EV-to-EBIT Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.39
Current: 0.39

During the past 13 years, the highest EV-to-EBIT of Immutep was 0.39. The lowest was 0.00. And the median was 0.00.

ASX:IMM's EV-to-EBIT is ranked better than
87.9% of 372 companies
in the Biotechnology industry
Industry Median: 13.35 vs ASX:IMM: 0.39

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Immutep's Enterprise Value for the quarter that ended in Dec. 2025 was A$513.68 Mil. Immutep's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil. Immutep's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was %.

Immutep  (ASX:IMM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Immutep's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2025 ) =EBIT / Enterprise Value (Q: Dec. 2025 )
=0/513.675215
= %

Immutep's Enterprise Value for the quarter that ended in Dec. 2025 was A$513.68 Mil.
Immutep's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immutep EV-to-EBIT Related Terms

Immutep EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Immutep's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immutep EV-to-EBIT Chart

Immutep Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.85 -5.38 -6.31 -5.82 -3.62

Immutep Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -3.62 0.00 0.00 0.00

ASX:IMM vs VRTX, REGN, ALNY: EV-to-EBIT Comparison

For the Biotechnology subindustry, Immutep's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Immutep's EV-to-EBIT falls into.


Immutep EV-to-EBIT Calculation

Immutep's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-24.234/0
=

Immutep's current Enterprise Value is A$-24.23 Mil.
Immutep's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immutep Business Description

Address 264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.